Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.exelixis.com
Exelixis, Inc. News Releases
Get the latest updates from Exelixis, Inc. News Releases directly as they happen.
Follow now 104 followers
Latest posts
Last updated 2 months ago
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
2 months ago
- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb...
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
3 months ago
– Total Revenues of $599 million for the Fourth Quarter of 2025...
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
3 months ago
– The FDA assigned a Prescription Drug User Fee Act target action...
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
3 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
4 months ago
– Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product...
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
4 months ago
– STELLAR-316 will use Natera’s Signatera™ assay to identify MRD-positive patients for...
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
4 months ago
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan...
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
5 months ago
- Event to Review R&D Progress and Outline Exelixis’ Strategy for Building...
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
6 months ago
– Presentations to be webcast on www.exelixis.com – ALAMEDA, Calif. --(BUSINESS WIRE)--Nov...
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
6 months ago
- Total Revenues of $597.8 million , Cabozantinib Franchise U.S. Net Product...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
7 months ago
– Conference Call and Webcast to Follow at 5:00 p.m. ET /...
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
7 months ago
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9...